SCHEMBL17877015

SCHEMBL17877015

O=C(O)c1cc2c(cc1CO)CCC2

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.44
HSD17B10 Q99714 2/20 0.43
KDM4E B2RXH2 1/20 0.43
HPGD P15428 1/20 0.43
DAO P14920 1/20 0.38
ALOX15 P16050 1/20 0.38
TSHR P16473 1/20 0.38
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
ATM Q13315 1/20 0.37
RXRB P28702 6/20 0.36
RXRA P19793 6/20 0.36
RXRG P48443 4/20 0.36
NPC1 O15118 4/20 0.36
RAB9A P51151 4/20 0.36
RXFP1 Q9HBX9 1/20 0.34
XDH P47989 1/20 0.34
SLC22A12 Q96S37 1/20 0.34
MRGPRX4 Q96LA9 2/20 0.33
POLB P06746 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL819768 0.81 ALDH1A1 (0.56) ALDH1A1HSD17B10KDM4EHPGDDAO
SCHEMBL28324640 0.79 HMGB1 (0.45) ALDH1A1HSD17B10HPGDALOX15TSHR
SCHEMBL818480 0.77 ALDH1A1 (0.59) ALDH1A1HSD17B10KDM4EHPGDDAO
SCHEMBL12536776 0.74 HMGB1 (0.42) ALDH1A1HSD17B10HPGDALOX15TSHR
Trimethylammonium SCHEMBL27854577 0.74 ALDH1A1 (0.48) ALDH1A1HSD17B10KDM4EHPGDDAO
SCHEMBL21682098 0.74 ALDH1A1 (0.48) ALDH1A1HSD17B10KDM4EHPGDDAO
SCHEMBL1506488 0.72 ALDH1A1 (0.47) ALDH1A1HSD17B10KDM4EHPGDDAO
SCHEMBL4110773 0.71 ALDH1A1 (0.46) ALDH1A1HSD17B10KDM4EHPGDDAO
SCHEMBL24824329 0.69 ALDH1A1 (0.48) ALDH1A1KDM4ETSHRMEN1KMT2A
SCHEMBL13328351 0.69 KEAP1 (0.42) ALDH1A1HSD17B10KDM4EHPGDALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180065976-A1 DERIVATIVES OF UNCIALAMYCIN, METHODS OF SYNTHESIS AND THEIR USE AS ANTITUMOR AGENTS WILLIAM MARSH RICE UNIVERSITY (US) 2018-03-08 US disclosed
US-9777013-B2 Derivatives of uncialamycin, methods of synthesis and their use as antitumor agents WILLIAM MARSH RICE UNIVERSITY (US) 2017-10-03 US disclosed
US-20160185791-A1 DERIVATIVES OF UNCIALAMYCIN, METHODS OF SYNTHESIS AND THEIR USE AS ANTITUMOR AGENTS WILLIAM MARSH RICE UNIVERSITY (US) 2016-06-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160185791-A1 DERIVATIVES OF UNCIALAMYCIN, METHODS OF SYNTHESIS AND THEIR USE AS ANTITUMOR AGENTS UNC119, UNC93B1, RIOX2 ALDH1A1 1893/4885HSD17B10 2441/4885KDM4E 1492/4885
US-20180065976-A1 DERIVATIVES OF UNCIALAMYCIN, METHODS OF SYNTHESIS AND THEIR USE AS ANTITUMOR AGENTS UNC119, UNC93B1, RIOX2 ALDH1A1 1977/4885HSD17B10 2304/4885KDM4E 1770/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.